013 weight-management mechanisms — plainly explained
GLP-1 receptor agonist (Wegovy / Saxenda). Glucagon-Like Peptide-1 is a hormone your gut produces after eating that signals 'I'm full' to your brain.
Wegovy (semaglutide, once-weekly pen) and Saxenda (liraglutide, daily pen) are SYNTHETIC versions of this hormone — when injected, they amplify the natural fullness signal, slow gastric emptying, and improve insulin sensitivity. The result: you eat less, you feel full faster, you store less fat.
Average weight loss in clinical trials: 10-15% body weight over 6–12 months on Wegovy; ~8% on Saxenda. FDA-approved 2021 (Wegovy) and 2014 (Saxenda).
V-Sculpt (HIFU + Thread Lift + RF stack). NOT a weight-loss tool.
V-Sculpt is body contouring — it sculpts the shape of fat that's ALREADY there without reducing total body weight. HIFU heats subcutaneous fat at SMAS depth (~4.5 mm), thread lifts physically reposition tissue, RF tightens overlying skin.
Result: trimmer silhouette in the treated area, but the scale weight stays the same. Best for patients with NORMAL BMI who have stubborn localised pockets (love handles, inner thigh, posterior arm, lower abdomen).
DCA (Deoxycholic Acid) injection. A bile-salt molecule that dissolves the membrane of fat cells, causing them to rupture and clear via the body's natural macrophage system over 4–6 weeks.
Best for SMALL focal pockets — sub-mental (double-chin), pre-jowl, posterior bra fold. NOT for systemic weight loss (too painful + too many injections required for large areas).
Typical course: 2–4 sessions, 4–6 weeks apart. Result builds 6–12 weeks post-final-session.
02Decision tree — BMI determines the right starting tool
Profile A — BMI ≥ 30 (clinical obesity). Recommendation: GLP-1 pen (Wegovy or Saxenda) as primary intervention. 10–15% weight loss matters MORE than body contouring at this BMI.
V-Sculpt and DCA are inappropriate first steps — there's too much fat for localised tools to make a meaningful difference. Sometimes we combine GLP-1 with bariatric surgery referral if BMI ≥ 35 with comorbidities.
Profile B — BMI 27–29 with weight-related comorbidities (diabetes, hypertension, sleep apnea). Recommendation: GLP-1 pen FIRST for 6–12 months.
Once BMI is in normal range, V-Sculpt can sculpt remaining stubborn pockets. The order matters — body contouring on a still-overweight body produces underwhelming visible results.
Profile C — BMI 25–27, overall healthy body weight but visible 'mom-pouch' / 'spare tire' / inner-thigh fat that won't respond to diet + exercise. Recommendation: V-Sculpt for the targeted pocket.
GLP-1 is over-spec for this case; DCA is under-spec (too much fat for an injectable). V-Sculpt's HIFU + thread combination is the right tool.
Profile D — Normal BMI, focal cosmetic concern (double-chin, pre-jowl fat pocket, posterior arm fat ring). Recommendation: DCA injection (2–4 sessions).
The pocket is small enough for an injectable to work; V-Sculpt would be over-spec for a 5-10cc fat pocket.
When NOT to start ANY of these: pregnancy / breastfeeding; severe kidney/liver disease; personal/family history of medullary thyroid cancer (GLP-1 contraindication); active gallbladder disease (DCA contraindication); pacemaker in treatment zone (V-Sculpt RF contraindication). Standard exclusions — consultation confirms.
03GLP-1 pen deep-dive — Wegovy vs Saxenda, the honest comparison
Wegovy (semaglutide, Novo Nordisk). Once-weekly subcutaneous pen.
FDA-approved June 2021 for weight management at BMI ≥ 30 or ≥ 27 with comorbidities. Average weight loss in STEP trials: 14.9% body weight over 68 weeks (Wegovy 2.4mg) vs 2.4% on placebo.
Dose titration: start at 0.25mg week 1-4, increase monthly to maintenance 2.4mg by week 17. Half-life ~7 days so you only inject once weekly.
Common side effects: nausea (44% in early weeks, fades by month 3), constipation, fatigue. Cost in Thailand: ฿18,500/pen × 12 weeks = ฿49,500 for a 12-week loading course (full program 6 months ~฿99,500).
Saxenda (liraglutide, Novo Nordisk). Once-DAILY subcutaneous pen.
FDA-approved 2014 for weight management. Average weight loss in SCALE trials: ~8% body weight over 56 weeks (Saxenda 3.0mg) vs ~3% on placebo.
Dose titration: start at 0.6mg daily, increase weekly to maintenance 3.0mg by week 5. Half-life ~13 hours so daily injection is required.
Common side effects: same profile as Wegovy but slightly lower nausea rate due to smaller per-dose amount. Cost in Thailand: ฿18,500/pen × ~1 pen per 17 days = ~฿32,500/month, ~฿195,000 over 6 months (more expensive total than Wegovy due to daily dosing).
Which to choose: Wegovy is the right default for most patients — higher weight loss, weekly injection (vs daily), and lower 6-month total cost. Saxenda makes sense when (a) you want the longer real-world safety track record (10+ years vs ~5 for Wegovy), or (b) Wegovy is out of stock (occasional manufacturing supply issues).
Both are SAME mechanism class; choose by lifestyle fit, not by which one is 'better'.
Why we use Wegovy/Saxenda only (not compounded semaglutide). Compounded semaglutide ('off-brand GLP-1' sold cheaper at telehealth shops + medspas) is NOT FDA-approved, NOT Thai-FDA-approved, and the active ingredient sourcing is unverified.
We've seen patients arrive with compounded-GLP-1 side-effects (severe nausea, gastroparesis) that wouldn't occur on the regulated Novo Nordisk product. Cost savings ~30-40% but safety profile is not equivalent.
04V-Sculpt vs DCA — when the concern is localised, which one fits
Choose V-Sculpt when: the pocket is medium-to-large (≥ 100 cc fat volume — roughly a flat-palm spread). V-Sculpt's combined HIFU + thread + RF stack treats the full area uniformly.
Typical zones: lower abdomen, love handles, inner thigh, posterior arm. ฿35,000/zone.
Result builds over 8–12 weeks; visible at 3 months.
Choose DCA when: the pocket is small + focal (< 50 cc) AND the patient is willing to tolerate 2–4 injection sessions. Typical zones: sub-mental (double-chin) ฿8,500/session × 2-4 sessions; pre-jowl pocket; small fat ring at posterior bra strap.
Result is permanent (the destroyed fat cells don't regenerate) but the patient WILL gain fat in OTHER zones if they overeat — DCA doesn't prevent future weight gain.
Combo (V-Sculpt + DCA): used for the rare patient with BOTH medium pocket AND focal sub-pocket within it. Example: lower abdomen V-Sculpt for the broad area, DCA touch-up for residual sub-umbilical pocket at month 3.
Total program ฿50,000–฿65,000.
What NOT to expect: neither V-Sculpt nor DCA reduces BMI or scale weight. Both reduce LOCAL fat volume in the treated area.
Patients who confuse 'body contouring' with 'weight loss' invariably leave disappointed. We're explicit about this at consultation — if your goal is the SCALE moving down, V-Sculpt and DCA are wrong tools; you need GLP-1 + diet + exercise.
05Bangkok 2026 pricing — what each program includes
GLP-1 pen program — Wegovy ฿18,500/pen (lasts ~4 weeks at maintenance dose). 12-week loading course ฿49,500. Full 6-month program ~฿99,500.
Saxenda ฿18,500/pen (lasts ~17 days at 3.0mg). 6-month program ~฿195,000. Both include monthly physician review + bloodwork at month 3 + dose-titration adjustments at no extra charge.
V-Sculpt body contouring — ฿35,000 per zone (lower abdomen, love handles, inner thigh, posterior arm, etc.). Includes HIFU + thread lift + RF in single 90-min session.
Result builds over 8-12 weeks. Touch-up at month 3 optional ฿15,000.
Bundle 2 zones ฿65,000 (save ฿5,000).
DCA injection — ฿8,500 per session. Sub-mental (double-chin) typical course 2-4 sessions = ฿17,000–฿34,000. Pre-jowl pocket 1-2 sessions = ฿8,500–฿17,000. Small posterior bra-strap pocket 2 sessions = ฿17,000.
What's INCLUDED in every program: physician consultation + photographs + post-procedure care + 24h follow-up + monthly review at no charge. Lab work (HbA1c, kidney function, lipid panel) at month 3 of GLP-1 program included.
We don't quote a 'starting price' then bill physician time, photos, or follow-up separately.
06The realistic timeline — and why patients who quit at month 2 lose nothing
GLP-1 month 1: dose titration phase. Patient is on 0.25mg → 0.5mg semaglutide.
Common: nausea 2-4 days after injection (fades by week 4), reduced appetite, no measurable weight loss yet. Patients who quit here lose nothing of value — they paid for the titration without reaching therapeutic dose.
GLP-1 month 2-3: maintenance dose reached. Weight loss starts becoming measurable — 3-5% body weight by month 3.
Nausea fades for most patients. Patients see clothes fitting differently before the scale shows large changes.
GLP-1 month 4-6: peak loss curve. Most weight comes off between month 4 and month 9.
Patients typically lose 8-12% body weight by month 6. This is also when the lab review at month 3 confirms metabolic markers improving (HbA1c, lipids, blood pressure).
GLP-1 month 7-12: plateau + maintenance. Weight loss slows as the body adapts.
Patients reach 10-15% loss by month 12 if they stay on maintenance dose AND maintain lifestyle changes. Stopping the medication causes ~50% rebound within 12 months if lifestyle hasn't changed — we discuss the exit strategy from month 3 onwards.
V-Sculpt timeline: immediate skin tightening visible in week 1 (temporary heat-shrink), flat-looking by month 1, real contouring visible by month 3, peak result month 6. After-photos scheduled at month 6.
DCA timeline: visible inflammation week 1-2 post-injection (swollen treated area, NORMAL response), settles by week 3-4, fat reduction visible 6-12 weeks after FINAL session. Don't judge result before month 3 of the last injection.
Ready to talk to our doctor?
Send a photo or describe your concern on LINE — we'll suggest a treatment plan and price range before you visit.